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Edited by Horst FeldmannAbstract The human ABCG2 (ABCP/MXR/BCRP) protein is
a recently recognized ABC half-transporter, which forms
homodimers in the plasma membrane and actively extrudes a
wide variety of chemically unrelated compounds from the cells.
This protein protects our cells and tissues against various
xenobiotics, with a crucial role in the intestine, liver, placenta,
and the blood–brain barrier. Moreover, ABCG2 seems to have a
key function in stem cell protection/regulation, and also in
hypoxic defense mechanisms. Widely occurring single nucleotide
polymorphisms in ABCG2 may aﬀect absorption and distribu-
tion, altering the eﬀectiveness and toxicity of drugs in large
populations. At the clinics, overexpression of ABCG2 in tumor
cells confers cancer multidrug resistance to a variety of newly
developed anticancer agents. On the other hand, speciﬁc
substrate mutants of ABCG2 are advocated for use as selectable
markers in stem-cell based gene therapy.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Polymorphic variant; Gene therapy; Hypoxic defense1. Introduction – ‘‘multidrug resistance’’ ABC transporters
ATP-binding cassette (ABC) proteins are present in all
known living species, with a relatively conserved structure
which contains a combination of conserved ABC and trans-
membrane (TM) domains (TMDs). In mammals, the func-
tionally active ABC proteins consist of at least four of such
domains, two TMDs and two ABCs. These domains may be
present within one polypeptide chain (full transporters), or
within two separate proteins (half-transporters). In this latter
case, functional ABC transporters need the dimerization of
speciﬁc half-transporters.* Corresponding author. Fax: +36-1-372-4353.
E-mail address: sarkadi@biomembrane.hu (B. Sarkadi).
Abbreviations: ABC transporters, ATP-binding cassette transporters;
ABCP, placenta-speciﬁc ABC transporter; ADME-TOX, absorption,
distribution, metabolism, and toxicity; BCRP, breast cancer resis-
tance protein; DOX, doxorubicin; MDR1, human multidrug resistance
protein (P-glycoprotein, ABCB1); MRP, human multidrug resistance
associated protein, ABCC1; MXR, mitoxantrone resistance protein;
Sf9 cells, Spodoptera frugiperda ovarian cells; TK, tyrosine kinase; TM,
transmembrane
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brane multiple times, typically forming six TM a-helices in each
TMD (see [1] and Fig. 1). The conformational changes within
the TM domains are believed to be responsible for the transport
of molecules through these transporters. The ABC regions are
the sites to bind and/or hydrolyze cytoplasmic ATP and, in the
active transporters, ATP hydrolysis ensures the energy for the
uphill transport of a substrate. The speciﬁc interaction of ABCs
with TMDs provides the transmission gear connecting substrate
binding and transport to the hydrolysis of ATP.
In humans, 49 ABC genes have been described and a con-
sistent nomenclature, based on sequence homology, has been
adopted. These proteins include regulated membrane channels,
e.g., the cystic ﬁbrosis TM conductance regulator (CFTR/
ABCC7), receptors also involved in complex channel forma-
tion, e.g., the sulfonylurea receptors (SUR/ABCC8 and 9), and
a large number of active transporters. In this latter case, ATP
hydrolysis is directly connected to substrate transport through
various cellular membranes (for reviews, see [2–5]).
Themultidrug transporter ABCproteins are plasmamembrane
glycoproteins which cause chemotherapy resistance in cancer by
actively extruding a large variety of therapeutic compounds from
the malignant cells. However, the same ABC transporters play an
important protective function against toxic compounds in a va-
riety of cells and tissues, especially in secretory organs, at the sites
of absorption, and in blood-tissue barriers (see [6,7]).
The three major multidrug resistance ABC proteins are
MDR1 (P-glycoprotein, ABCB1), multidrug resistance associ-
ated protein 1 (MRP1, ABCC1) and ABCG2 (placenta-speciﬁc
ABC transporter, ABCP/breast cancer resistance protein,
BCRP/mitoxantrone resistance protein, MXR). MDR1 and
MRP1 can transport a large variety of hydrophobic drugs, and
MRP1 can also extrude anionic drugs or drug conjugates. Ad-
ditional members of the MRP/ABCC family have also been in-
dicated to be involved in cancermultidrug resistance (for details,
see [8]). The transport properties of ABCG2 are overlapping
both with that of MDR1 and the MRP type proteins, thus
these three proteins form a special network in chemo-defense
mechanisms.2. Structure, transport properties and possible mechanism of
action of ABCG2
The G subfamily of ABC transporters consists of ﬁve half-
transporters with a domain arrangement, when the ABCation of European Biochemical Societies.
Fig. 1. Proposed membrane topology of the P-gp/MDR1 and the
ABCG2 multidrug transporters.
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chain. The suggested membrane topology of the human
ABCG2, based on various prediction models, is presented in
Fig. 1. The predicted glycosylation sites are also indicated in
this model. There has been no detailed study as yet for the
experimental veriﬁcation of this membrane topology, but the
double glycosylation of the protein, when expressed in mam-
malian cells, has already been documented [9]. It has also been
shown that the expression or transport function of ABCG2
does not require glycosylation, when the protein was expressed
in insect, Spodoptera frugiperda ovarian cells (Sf9 cells) (see
[10]). Membrane insertion and transport function most prob-
ably require the dimerization of ABCG2 (see below).
ABCG2 was ﬁrst cloned from the placenta and from mul-
tidrug-resistant tumor cells, not expressing either MDR1 or
MRP1 [11–13]. By now it has been established that ABCG2
functions as a high capacity drug transporter with wide sub-
strate speciﬁcity. This protein can transport large, hydro-
phobic, both positively or negatively charged molecules,
including cytotoxic compounds (mitoxantrone, topotecan,
ﬂavopiridol, methotrexate), ﬂuorescent dyes (e.g., Hoechst
33342) and diﬀerent toxic compounds found in normal food
(2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, PhIP) or
pheophorbide A [14–19].
ABCG2 mediates the extrusion of the transported com-
pounds towards the extracellular space through a process en-
ergized by ATP hydrolysis [20]. This active transport has been
directly observed in inside-out membrane vesicles, when
ABCG2 was shown to transport methotrexate [21].
It has been documented that ABCG2 shows a drug-stimu-
lated, vanadate-sensitive ATPase activity, which requires the
presence of Mg ions [9,10]. This ATPase activity, as in the case
of other multidrug transporters, reﬂects the substrate recog-
nition and is connected to substrate transport by this protein.
However, when the human ABCG2 is expressed in the Sf9
insect cell system, in isolated membranes a large fraction of
ABCG2-ATPase seems to be already activated by endogenous
substrates, and additional substrates have only a minor eﬀect
[10]. In contrast, in certain isolated mammalian cell mem-
branes, ABCG2-ATPase is signiﬁcantly activated by the
transported compounds (unpublished observations). More-over, when human ABCG2 was expressed in a bacterial (lac-
tobacillus) expression system, membrane cholesterol itself was
found to activate this protein [22]. Thus, endogenous lipids or
lipid derivatives may be natural transported substrates of
ABCG2.
The active, ATP-dependent transport properties of ABCG2
have also been documented by the formation of the ATPase
reaction cycle intermediate, trapped ADP, in this protein [10].
This ADP trapping reaction, which is stabilized by the ATPase
inhibitor vanadate, is a general feature of all known active
transporter ABC proteins [1]. Interestingly, in the case of
ABCG2 only the cobalt complex of 8-azido-ATP could be
used to obtain a covalent linkage of this trapped intermediate
to the protein. ABCG2 has only one ABC and one TM do-
main, therefore, it requires dimerization to become active.
There are several ﬁndings indicating that ABCG2 functions as
a homodimer. In drug-selected cell lines, an exclusive upreg-
ulation of the ABCG2 mRNA and the ampliﬁcation of the
abcg2 gene alone was enough to circumvent drug-toxicity
[13,23]. In mammalian or insect cells, transfected with the
ABCG2 cDNA, ABCG2 was fully functional [9,12]. More-
over, co-expression of an inactive ABCG2 variant with the
wild-type protein resulted in a loss of ABCG2 activity [24]. In
this latter study, the formation of ABCG2 homodimer,
bridged by a disulﬁde bond, was suggested.3. ABCG2 in cancer drug resistance
The overexpression of ABCG2 was observed in certain drug-
resistant cell lines and tumors, providing a special multidrug
resistant phenotype in these cancer cells. Human ABCG2 was
shown to confer resistance against various, clinically relevant
compounds, e.g., mitoxantrone, methotrexate, topotecan,
SN38, and ﬂavopiridol [13–15,25–27]. The ﬁrst cloning of
ABCG2 from either expressed sequence tags or heavily drug
selected cell lines yielded sequences coding for diﬀerent amino
acids at position 482 [3–5]. As discussed below, this single
amino acid change results in major diﬀerences in substrate
recognition and transport by ABCG2 (see Section 5, and
Fig. 2). Therefore, for some time, diﬀerent experimental ex-
pressions of ABCG2 yielded diﬀerent results regarding sub-
strate handling by this protein. Based on overwhelming
evidence, in the current review we refer to R482-ABCG2 as the
wild-type protein. Therefore, clinical anthracyclin resistance
probably cannot be caused by ABCG2, while in the case of
many new anticancer agents ABCG2 may be a candidate
transporter for cancer drug resistance (see Fig. 2). In fact,
polymorphic variants may further modulate substrate recog-
nition or transport activity of ABCG2, as discussed in
Section 5.
We have shown recently that the human ABCG2 multidrug
transporter interacts with two recently developed speciﬁc ty-
rosine kinase inhibitors (TKIs), Gleevec/Imatinib (STI-571)
and Iressa (ZD 1839), with a high aﬃnity [53]. In current an-
titumor drug research, a large variety of TKIs with increasing
speciﬁcity and selectivity have been developed. These are
highly promising agents for speciﬁc inhibition of malignant cell
growth and metastasis formation. However, their therapeutic
potential also depends on access to their intracellular targets,
which may be signiﬁcantly modulated by ABC membrane
Fig. 2. Transported substrates of the wild-type and R482G ABCG2
protein.
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TKIs may be an important factor in the treatment of cancer
patients, moreover, an extrusion of TKIs by ABCG2 may re-
sult in tumor cell TKI resistance. Based on the above described
role of ABCG2 in tumor resistance, the selective and sensitive
detection of the ABCG2 protein has a major importance in
cancer diagnostics and treatment. The best known experi-
mental approach in this regard is the analysis of the active
extrusion of the ﬂuorescent dye, Hoechst 33342 by ABCG2, by
using ﬂuorescence detection, e.g., ﬂow cytometry (see [16]).
Several other ﬂuorescent substrates of ABCG2 (e.g., topo-
tecan, ﬂavopiridol, BODIPY-prazosin or mitoxantrone) have
also been applied in this regard. However, this dye transport
assay is usually not speciﬁc for ABCG2, and the combined use
of ABCG2-speciﬁc inhibitors is suggested in these methods. A
recent report suggests that the chlorophyll derivative, pheo-
phorbide A, is an ABCG2 selective transported substrate that
can be used for ﬂow cytometry analysis of this protein [19].
Still, a highly sensitive and selective dye transport method,
which could be used for in vivo sorting of ABCG2 expressing
cells, is yet to be introduced.
The recent development of a monoclonal antibody, speciﬁ-
cally reacting with the human ABCG2 protein on the cell
surface, has been a major breakthrough in diagnostic appli-
cations [16]. This antibody was prepared by immunizing mice
with intact mouse ﬁbroblasts, expressing the human ABCG2.
The antibody, named 5D3, was reported to inhibit the Hoechst
33342 dye transport function of ABCG2 in intact cells [16].
Recently, we have found that detection and inhibition by 5D3
strongly depends on the actual conformation of ABCG2
(Varady et al., unpublished). This conformation-sensitive in-
teraction may be applied for the investigation of the molecular
mechanism and the detection of drug interactions of ABCG2.4. ABCG2 and tissue defense – ADME-TOX, stem cells and
hypoxia
It has been increasingly recognized that transporter-medi-
ated processes signiﬁcantly modulate drug absorption, distri-
bution, metabolism and excretion. By now it is well established
that active eﬄux by ABC transporters in the small intestine is a
major contributor to poor absorption and low bioavailability.
To be eﬀective, absorbed drugs must also enter various body
compartments, e.g., cross the blood–brain barrier, and thisentry is also modiﬁed by the eﬄux function of various ABC
transporters. Transporters are common sites for drug–drug
interactions, as well as interactions of drugs with endogenous
substrates. These eﬀects may lead to unexpected drug toxicity
and various adverse eﬀects (for recent review, see [7]).
The functional characteristics and the distribution of
ABCG2 suggest a major role of this protein in the tissue
protection against xenobiotics (see [28,29]). As mentioned
above, ABCG2 transports a large variety of hydrophobic or
partially hydrophobic molecules, and this protein was found to
be physiologically expressed in the canalicular membrane of
the liver, in the epithelia of small intestine, colon, lung, kidney,
adrenal and sweat glands, as well as in the endothelia of veins
and capillaries.
The development of abcg2 knock-out mice, achieved inde-
pendently in two diﬀerent laboratories [17,30], was a major
step in searching for the physiological functions of this trans-
porter. Although these knock-out animals are alive and show
no major pathology, several alterations have been observed
which can be connected to the lack of functional abcg2. In
combination with ABCG2 inhibitor studies, carried out in
normal subjects, these investigations suggested that ABCG2
has a major role in the modulation of the absorption of toxic
materials from food, as well as of that of several orally applied
pharmacological agents.
The Dutch group which developed an abcg2 knock-out
mice found that in these animals the combination of exposure
to light and an alphalpha diet, rich in chlorophyll, led to
phototoxic skin lesions [17]. These lesions were demonstrated
to be caused by the accumulation of a chlorophyll degrada-
tion product, pheophorbide A. As described below, in the
knock-out mice studies carried out in the USA, the authors
reported a role of ABCG2 in heme or related metabolite
transport [54].
In addition to the role of ABCG2 in absorption, an in-
creased biliary secretion of the transported compounds by
ABCG2 may also signiﬁcantly contribute to a decreased bio-
availability of various agents. Indeed, ABCG2 expression was
clearly shown to inﬂuence both the absorption and secretion of
the anticancer agent topotecan [26,31]. Although ABCG2 ex-
pression was reported in the blood–brain barrier [32], we have
no convincing data as yet about the role of this protein in this
barrier function. Interestingly, a high level expression of the
ABCG2 protein and its ﬂuorescent dye extrusion function has
been suggested to identify hemopoietic stem cells [16,33,34].
Moreover, this so called ‘‘side population’’ of progenitor cells,
actively extruding the ﬂuorescent Hoechst 33342 dye, seems to
represent pluripotent stem cells in a variety of tissue sources
[16,33–36]. Whether ABCG2 is required for a metabolic pro-
tection of stem cells, or may directly inﬂuence stem cell func-
tions, e.g., diﬀerentiation, is unclear at present [16,30,37].
Recent results of Krishnamurthy et al. [54] indicate that
ABCG2 expression provides an important cell survival ad-
vantage under hypoxic conditions. Progenitor cells obtained
from abcg2 knock-out mice showed a reduced ability to form
colonies under hypoxia. Moreover, blocking of abcg2 function
in normal progenitor cells reduced survival under hypoxic
conditions. In both cases, blockade of heme/porphyrin syn-
thesis reversed this hypoxic susceptibility. Cells overexpressing
ABCG2 accumulated lower amounts of porphyrin, heme was
speciﬁcally bound to ABCG2, and drug transport by ABCG2
was signiﬁcantly modulated by heme. ABCG2 expression was
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response elements in the ABCG2 promoter region. These
studies suggest that ABCG2 permits enhanced cell survival in
oxygen poor environments by reducing the accumulation of
toxic heme metabolites. These ﬁndings have important impli-
cations for the chemotherapeutic treatment of solid tumors
with stimulated ABCG2 expression under hypoxia and for the
survival of stem cells in transplantation.Fig. 3. Gene-therapy application of the mutant ABCG2 as a selectable
marker protein.5. Mutant and polymorphic variants of ABCG2
There is little information about the structural elements re-
sponsible for the substrate recognition and transport by
ABCG2. The TMDs of ABC transporters are thought to be
responsible for the recognition of transported substrates. In
the case of MDR1, deletion mutants containing only the
TMDs still retained their substrate binding capacity [38].
Moreover, diﬀerent studies identiﬁed a number of amino acids
in various TM helices of MDR1 and MRPs, thought to form
the drug-binding domain in these proteins [38–41].
In the case of ABCG2, in drug-selected cell lines, overex-
pressing human or mouse ABCG2, a single amino acid change
in aa. position 482 occurred [42,43]. The mutants having
R482G or R482T (R482M or R482S in the mouse abcg2)
showed altered substrate speciﬁcity as compared to the wild-
type protein, i.e., they conferred increased mitoxantrone or
doxorubicin (DOX) resistance and rhodamine 123 transport
capacity (see Fig. 2, [42,43]). In fact, these R482 mutants have
increased transport and ATP hydrolytic activity, therefore they
are considered as ‘‘gain of function’’ mutants [10]. However,
the R482G and R482T mutants were not able to transport
methotrexate, which is a transported substrate of the wild-type
ABCG2 [15,44].
In a recent study [45], several amino acids in the TM helices
of ABCG2 have been mutated and the protein variants were
analyzed by measuring drug resistance in intact cells. The
mutants showed signiﬁcantly diﬀerent drug resistance patterns,
indicating the importance of these residues in the substrate
speciﬁcity of ABCG2. In a recent, detailed study we have ex-
pressed nine diﬀerent ABCG2 position 482 variants in Sf9 cells
[€Ozvegy et al, unpublished], and demonstrated that an ex-
change of this single amino acid was not detrimental for the
correct folding or basic transport activity of ABCG2, but in-
duced major alterations in both the transport activity and
substrate speciﬁcity of this protein. These variants may be
applied to express this multidrug transporter with the desired
transport proﬁle for various cell protection applications (see
below).
Recent studies have identiﬁed two frequently occurring
polymorphisms in ABCG2, which are non-synonymous SNPs,
resulting in amino acid substitution in the coding region of the
protein. These SNPs yield ABCG2 variants containing V12M
and Q141K. When these variants were expressed in mamma-
lian or insect cells, a diﬀerent pattern of drug resistance, and a
signiﬁcantly altered transport capacity and substrate handling
has been observed [46,47] [Morisaki et al., unpublished].
Population data for the actual frequency of these variants, the
possible eﬀects of the wild-type/variant heterodimerization
(probably present in heterozygous individuals) and the detailed
functional characterization of the ABCG2 variants are chal-
lenging tasks in this research area.6. ABCG2 in stem cells – possible gene therapy applications
The co-expression of a human drug-resistance protein with a
therapeutic gene product should allow both an enrichment of
the corrected cells and an in vivo drug selection during clinical
gene therapy. The use of the MDR1-P-glycoprotein as such a
selectable marker has been widely investigated and advocated,
while other studies reported major problems with this ap-
proach (see [48–51]).
Recent studies in our laboratory suggest that a mutant
ABCG2 protein is an ideal candidate for human stem cell
protection and for use as a selectable marker in gene therapy
(Fig. 3). The cDNA encoding this protein is relatively small
(about 2 kbase) and the active dimer is spontaneously formed
in the overexpressing cells [52]. Since the R482G variant of
ABCG2 has diﬀerent substrate speciﬁcity than the wild-type
protein (Fig. 2), this mutant has a special advantage in gene
therapy applications.
We have documented that when the mutant ABCG2 was co-
expressed with a therapeutic gene, the expression of the ther-
apeutic gene in hematopoietic progenitor cells corrected the
loss-of-function mutation responsible for human chronic
granulomatous disease. At the same time, the mutant ABCG2
protein selectively protected the transduced cells against clin-
ically applicable cytotoxic agents. Overexpression of ABCG2
did not aﬀect in vitro hematopoietic cell maturation or the
restoration of granulocyte function by the therapeutic gene.
The in vivo applicability of such a tailor-made drug resistance
ABC transporter as selectable marker still awaits further
studies.7. Conclusions and perspectives
The human ABCG2 protein is clearly a multi-task trans-
porter, having important roles in a variety of physiological and
pathological functions. Protection of our tissues, including the
stem cells, against xenobiotics and hypoxia, modulation of
drug absorption and distribution, are the positive sides of
ABCG2 expression. In contrast, multidrug resistance caused
by ABCG2 is a major challenge at the cancer clinics. However,
even this drug resistance function may be put to good use in
medical therapy, since the application of ABCG2 may pro-
mote stem-cell based gene therapy.
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